Scientific Advisor Bio Dr. Christine Brown is the Heritage Provider Network Professor in Immunotherapy at City of Hope Comprehensive Cancer Center. Her research has focused on advancing chimeric antigen receptor (CAR) T cell therapy for the treatment of cancer. As Deputy Director of the T Cell Therapeutics Research Laboratory (TCTRL), Dr. Brown provides scientific oversight…

Mark Leuchtenberger, MBA, is also currently Interim CEO of Brooklyn ImmunoTherapeutics and formerly Chairman, President and CEO of IRX Therapeutics.

Scientific Advisor Bio Assistant member, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center. Member investigator, The Parker Institute for Cancer Immunotherapy. Dr. Klebanoff is cellular immunologist and medical oncologist with 17 years of experience in the pre-clinical and clinical development of T cell-based immunotherapies for the treatment of solid and hematologic cancers. Prior to…

Scientific Advisor Bio Dr. Tasian is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia and University of Pennsylvania who is interested in development of molecularly-targeted therapeutics for children with high-risk leukemias. Her translational laboratory research program focuses upon testing of kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic…

Mark Leuchtenberger, MBA, is also currently Interim CEO of Brooklyn ImmunoTherapeutics and formerly Chairman, President and CEO of IRX Therapeutics.

SAB Head - Moffitt Cancer Center

Executive leadership at the Moffitt Cancer Center for Applied Science, Center for Translational Research, Adam Comprehensive Melanoma Center. The McGillicuddy Endowed Chair for Melanoma Research and Treatment.

General Partner - Advent

Chairman of Aleta’s BOD, Founder & board leadership roles at Glycosciences, Galapagos, Celldex, trained at Oxford.

Operating Partner - Advent

20+ years of senior leadership experience in life science companies. Former CEO of Karus Therapeutics, former head of BD at Ablynx.

Director - Aleta

Founder/co-founder of 7 biotechs including Avila Therapeutics ($355M Celgene acquisition). Advent Life Sciences venture partner. Former head of Biogen R&D, asst. professor pathology at HMS, PhD Univ. Oxford (Chemistry)

President & CSO - Aleta

PI, Biogen: Inflammation, autoimmunity, fibrosis, oncology. Since 2012 focused on new company development. Author on more than 30 patents and approx. 100 publications & recent IO reviews.